Suicidal Behavior and Depression in Smoking Cessation Treatments
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Two treatments for smoking cessation--varenicline and bupropion--carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression. However, some epidemiological studies report an increased risk in smoking or smoking cessation independent of treatment, and differences between drugs are unknown. METHODOLOGY: From the FDA's Adverse Event Reporting System (AERS) database from 1998 through September 2010 we selected domestic, serious case reports for varenicline (n = 9,575), bupropion for smoking cessation (n = 1,751), and nicotine replacement products (n = 1,917). A composite endpoint of suicidal/self-injurious behavior or depression was defined as a case with one or more Preferred Terms in Standardized MedDRA Query (SMQ) for those adverse effects. The main outcome measure was the ratio of reported suicide/self-injury or depression cases for each drug compared to all other serious events for that drug. RESULTS: Overall we identified 3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement. Compared to nicotine replacement, the disproportionality results (OR (95% CI)) were varenicline 8.4 (6.8-10.4), and bupropion 2.9 (2.3-3.7). The disproportionality persisted after excluding reports indicating concomitant therapy with any of 58 drugs with suicidal behavior warnings or precautions in the prescribing information. An additional antibiotic comparison group showed that adverse event reports of suicidal/self-injurious behavior or depression were otherwise rare in a healthy population receiving short-term drug treatment. CONCLUSIONS: Varenicline shows a substantial, statistically significant increased risk of reported depression and suicidal/self-injurious behavior. Bupropion for smoking cessation had smaller increased risks. The findings for varenicline, combined with other problems with its safety profile, render it unsuitable for first-line use in smoking cessation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They found a higher number of reports of suicidality/self-injurious behavior among patients using NRTs (N = 50) compared to those using antibiotics (N = 21).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, both varenicline and bupropion were observed to have far higher numbers of individuals who experienced suicidal ideation (N = 1135 and N = 73), attempts (N = 323 and N = 56), behaviors (N = 63 and N = 1), and completions (N = 272 and N = 19) than individuals who were taking NRTs.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their evaluation of case reports of adverse events reported to the FDA, Moore et al.28 found that the odds ratio for suicide was elevated for bupropion compared to the antibiotic comparison group (OR: 12.5; CI: 9.1–17.2).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moore et al.28 found that 90% of the 3,249 FDA-reported cases of suicidal/self-injurious behavior or depression associated with smoking cessation pharmacotherapies were found in individuals taking varenicline. This included 272 (92%) of the reported completed suicides and 323 (85%) of all reported suicide attempts.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“However, the evidence supporting their conclusion is somewhat limited, as they did not include a comparison group of individuals attempting to quit smoking without any pharmacotherapy.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders ( DSM ‐ IV ‐ TR )
Segal, D. L. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0271 · Cited by 4,666
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464 · cited 1×
“Treatment Efficacy The efficacy of the three major pharmacological interventions for smoking cessation has been studied in numerous randomized clinical trials [33,34].”
Background(2010) · PsycEXTRA Dataset · doi:10.1037/e590462011-001 · Cited by 1,803
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“adverse event data that escape detection in clinical trials because of their rarity or uncertain event ascertainment [24–27].”
BackgroundEffects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801 · cited 1×
“These reports provided stronger evidence for other withdrawal symptoms such as irritability, insomnia, and weight gain, [8–10] which suggests that depression is not common in nicotine withdrawal.”
ResultAubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344 · cited 1×
“The only published trial comparing varenicline to nicotine patches found no statistically significant difference in reported 7-day abstinence at 52 weeks [37].”
BackgroundPharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg, M. J., Filion, K. B., Yavin, D., Belisle, P., Mottillo, S., Joseph, L., Gervais, A., O'Loughlin, J., Paradis, G., Rinfret, S., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070256 · Cited by 318 · cited 1×
“Treatment Efficacy The efficacy of the three major pharmacological interventions for smoking cessation has been studied in numerous randomized clinical trials [33,34].”
BackgroundSingh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Self-citationThe Global Research Neglect of Unassisted Smoking Cessation: Causes and Consequences
Chapman, S., & MacKenzie, R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000216 · Cited by 237 · cited 1×
“Retrospective studies of successful quitters often favor self quitters or cold turkey approaches [35].”
Background
Research works printed but not linked: 2
- Josefberg H 2006 Clinical Safety Review Application 21-928 Varenicline tartrate Silver Spring, MD U.S. Food and Drug Administration, Center for Drug Evaluation and Research
- Winchell C 2006 Supervisory Review of NDA: Safety Review and Primary Clinical Efficacy Review Varenicline Pfizer Inc.U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Cited by
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., Oliveira, G. M. M. D., Simão, A. F., Dutra, O. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R. M. D. S., Giuliano, I. D. C. B., Alencar Filho, A. C. D., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 434
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Drug safety assessment in clinical trials: methodological challenges and opportunities
Singh, S., & Loke, Y. K. (2012) · Trials · doi:10.1186/1745-6215-13-138 · Cited by 227
“In a recent review of regulatory actions by the FDA in 2009 [18], approximately two thirds of major regulatory actions on drug safety, including boxed warnings, withdrawals and contraindications, relied on spontaneous case reports [19].”
BackgroundSelf-citationSupporting smoking cessation: a guide for health professionals.
Zwar, N. A., RICHMOND, R. L., Borland, R., Peters, M. J., Litt, J., Bell, J., Caldwell, B., & Ferretter, I. T. (2012) · Cited by 226
The vigilance regulation model of affective disorders and ADHD
Hegerl, U., & Hensch, T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.008 · Cited by 212
“In this espect, it should be noted that partial agonist varenicline has also een associated with significant increases in suicidal behaviour in moking cessation (Moore et al., 2011).”
BackgroundHoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P., & Overstreet, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0150-2 · Cited by 211
Lindson, N., Theodoulou, A., Ordóñez-Mena, J. M., Fanshawe, T. R., Sutton, A. J., Livingstone-Banks, J., Hajizadeh, A., Zhu, S., Aveyard, P., Freeman, S. C., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015226.pub2 · Cited by 177
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Thomas, K. H., Dalili, M. N., López-López, J. A., Keeney, E., Phillippo, D., Munafo, M. R., Stevenson, M., Caldwell, D. M., & Welton, N. J. (2021) · Health Technology Assessment · doi:10.3310/hta25590 · Cited by 171
Smoking cessation, version 1.2016, NCCN clinical practice guidelines in oncology
Shields, P. G., Herbst, R. S., Arenberg, D., Benowitz, N. L., Bierut, L., Luckart, J. B., Cinciripini, P., Collins, B., David, S., Davis, J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0152 · Cited by 146
Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events
Gibbons, R. D., & Mann, J. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12121599 · Cited by 142
“As previously noted, a possible safety signal for varenicline (relative to bupropion and nicotine replacement therapy) has been reported (5) for depression and suicidal events.”
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
“Using post-marketing spontaneous reporting data, a recent study showed an increased risk of reported depression and suicidal/self-injurious behaviour with bupropion compared to NRT [58].”
BackgroundCinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136
“The results using this type of ongoing assessment are informative given the postmarketing reports associating varenicline use with increased depression and related affective disturbances, such as anxiety and hostility.(13,32) Moreover, no differences between the groups were noted in self-reported neuropsychiatric adve…”
Anthenelli, R. M., Morris, C., Ramey, T. S., Dubrava, S. J., Tsilkos, K., Russ, C., & Yunis, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-6-201309170-00005 · Cited by 135
Thomas, K. H., Martin, R. M., Davies, N. M., Metcalfe, C., Windmeijer, F., & Gunnell, D. (2013) · BMJ · doi:10.1136/bmj.f5704 · Cited by 119
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
Smith, P. H., Weinberger, A. H., Zhang, J., Emme, E., Mazure, C. M., & McKee, S. A. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw144 · Cited by 133
Zwar, N. A., Mendelsohn, C. P., & RICHMOND, R. L. (2014) · BMJ · doi:10.1136/bmj.f7535 · Cited by 101
Carim-Todd, L., Mitchell, S. H., & Oken, B. S. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.04.014 · Cited by 82
“However, to date, pharmacological treatments produce side effects (varenicline has been associated with depression and cardiovascular disease [Moore et al., 2011; Singh et al., 2011]), and have shown modest efficacy in the long term (12-month abstinence rates have been lower than 30%; Alberg et al.”
BackgroundPattern of perioperative gabapentinoid use and risk for postoperative naloxone administration
Deljou, A., Hedrick, S. J., Portner, E. R., Schroeder, D. R., Hooten, W. M., Šprung, J., & Weingarten, T. N. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2017.11.113 · Cited by 84
“In fact, the majority of regulatory actions on drug safety arise from case reports.(9,10) To that end, we have reported that the administration of gabapentinoids before both elective joint arthroplasty surgery and laparoscopic surgery increased the risk for”
BackgroundSmoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Shields, P. G., Bierut, L. J., Arenberg, D. A., Balis, D. S., Cinciripini, P. M., Davis, J. M., Edmondson, D. M., Feliciano, J., Hitsman, B. L., Hudmon, K. S., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0013 · Cited by 93
Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., & Quik, M. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194852 · Cited by 70
“In addition, varenicline is not without side effects, including nausea and serious psychiatric problems (Jorenby et al., 2006; Moore et al., 2011; Williams et al., 2011).”
BackgroundMercié, P., Arsandaux, J., Katlama, C., Ferret, S., Beuscart, A., Spadone, C., Duvivier, C., Reynes, J., Wirth, N., Moinot, L., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30002-x · Cited by 71
Pharmacotherapy for Substance Use Disorders
Klein, J. W. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.011 · Cited by 71
Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression
Gandelman, J. A., NEWHOUSE, P. A., & Taylor, W. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.018 · Cited by 68
“Early case reports of varenicline in smokers suggested increased depressive and suicidal behavior (Harrison-Woolrych and Ashton, 2011; Moore et al., 2011; Williams et al., 2011), however a recent meta-analysis of placebo controlled trials concluded the evidence did not support increased risk for…”
Higgins, G. A., Silenieks, L. B., Lau, W., de Lannoy, I. A. M., Lee, D. K. H., Izhakova, J., Coen, K. M., Lê, A. D., & Fletcher, P. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2919-2 · Cited by 62
Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C. H., & Fazel, S. (2015) · BMJ · doi:10.1136/bmj.h2388 · Cited by 54
Adapting Smoking Cessation Treatment According to Initial Response to Precessation Nicotine Patch
Rose, J. E., & Behm, F. M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070919 · Cited by 51
“One recent meta-analysis linked varenicline with a slight excess risk for heart attack (11), and questions have been raised about its appropriateness as a first-line pharmacotherapy (8).”
BackgroundTobacco Smoking: Patterns, Health Consequencesfor Adults, and the Long-term Health of the Offspring
Maritz, G. S., & Mutemwa, M. (2012) · Global Journal of Health Science · doi:10.5539/gjhs.v4n4p62 · Cited by 63
“Suicidal thoughts are associated with bupropion and varenicline (Moore et al., 2011).”
BackgroundThe Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2012) · The Scientific World Journal · doi:10.1100/2012/104105 · Cited by 44
“Although one report found that varenicline was associated with an increased rate of such events [63], other large studies have generally found no difference between varenicline and other medications for smoking cessation [64–67], findings that have been replicated in studies sponsored by the U.”
ResultRespiratory depression in the post-anesthesia care unit: Mayo Clinic experience
Laporta, M. L., Šprung, J., & Weingarten, T. N. (2020) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2020.4816 · Cited by 53
“However, randomized prospective trials and the resultant meta-analyses are known to underreport risk from real-world use [40-42].”
BackgroundNew insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bağdaş, D., Alkhlaif, Y., Jackson, A. B., Carroll, F. I., Ditre, J. W., & Damaj, M. I. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.025 · Cited by 43
The evolutionary old forebrain as site of action to develop new psychotropic drugs
LOONEN, A. J. M., & Ivanova, S. А. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798617 · Cited by 41
“Numerous reports illustrate varenicline’s potential to induce neuropsychiatric side effects (including depression) (Ahmed et al., 2013; Moore et al., 2011) and aggression towards others (Moore et al.”
BackgroundWu, Q., Gilbody, S., Peckham, E., Brabyn, S., & Parrott, S. (2016) · Addiction · doi:10.1111/add.13415 · Cited by 39
Mocking, R. J. T., Pflanz, C. P., Pringle, A., Parsons, E., McTavish, S. F. B., Cowen, P. J., & Harmer, C. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.205 · Cited by 42
“Cohort studies can be subject to several forms of biases, including stimulated reporting through media awareness (Moore et al, 2011).”
BackgroundResultJain, R., Jhanjee, S., Jain, V., Gupta, T., Mittal, S., Goelz, P., Wileyto, E. P., & Schnoll, R. A. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntt115 · Cited by 37
Standardizing adverse drug event reporting data
Wang, L., Jiang, G., Li, D., & Liu, H. (2014) · Journal of Biomedical Semantics · doi:10.1186/2041-1480-5-36 · Cited by 44
“However, most of existing studies on the AERS were carried out for a small number of drugs [6,8-10], and few studies were focused on large-scale mining or on detecting the etiology of ADE signals in terms of mechanism of action, physiologic effect, or molecular structure of drugs [11].”
BackgroundSala, M., Braida, D., Pucci, L., Manfredi, I., Marks, M. J., Wageman, C. R., Grady, S. R., Loi, B., Fucile, S., Fasoli, F., et al. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02204.x · Cited by 39
“However, serious side effects have been reported in patients taking varenicline including adverse cardiovascular effects and/or neuropsychiatric events such as (but not limited to) depression, suicidal ideation, suicide attempts and completed suicide (Freedman, 2007; Moore et al., 2011; Singh et al., 2011).”
BackgroundStokes, C., & Papke, R. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.035 · Cited by 35
“effects for varenicline, while there have been fewer such reports for cytisine (Moore et al., 2011; Shytle et al., 2011).”
Lindson, N., Theodoulou, A., Livingstone‐Banks, J., Aveyard, P. N., Fanshawe, T. R., Ordóñez-Mena, J. M., Sutton, A. J., Freeman, S. C., Agrawal, S., & Hartmann‐Boyce, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015226 · Cited by 33
Issa, J. S., Abe, T. O., Moura, S., Santos, P. C. J. L., & Pereira, A. C. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts230 · Cited by 32
Brunzell, D. H. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts089 · Cited by 38
Ponzoni, L., Braida, D., Pucci, L., Donzelli, A., Fasoli, F., Manfredi, I., Papke, R., Stokes, C., Cannazza, G., Clementi, F., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3619-x · Cited by 31
“2006; Zierler-Brown and Kyle 2007), but adverse cardiovascular effects and/or neuropsychiatric events have recently been reported including (but not limited to) depression, suicidal ideation, suicide attempts, and completed suicide (Freedman 2007; Moore et al. 2011; Singh et al. 2011).”
BackgroundUse of varenicline versus bupropion and risk of psychiatric adverse events
Pasternak, B., Svanström, H., & Hviid, A. P. (2013) · Addiction · doi:10.1111/add.12165 · Cited by 31
Powell, G. L., Leyrer‐Jackson, J. M., Goenaga, J. G., Namba, M. D., Piña, J., Spencer, S. M., Stankeviciute, N. M., Schwartz, D., Allen, N. P., Franco, A. P. D., et al. (2019) · Physiological Reports · doi:10.14814/phy2.13958 · Cited by 33
Motooka, Y., Matsui, T., Slaton, R. M., Umetsu, R., Fukuda, A., Naganuma, M., Hasegawa, S., Sasaoka, S., Hatahira, H., Iguchi, K., et al. (2018) · SAGE Open Medicine · doi:10.1177/2050312118777953 · Cited by 31
Lange‐Asschenfeldt, C., Schäble, S., Suvorava, T., Gholamreza-Fahimi, E., Bisha, M., Stermann, T., Henning, U., & Kojda, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.025 · Cited by 27
Yousefi, M. K., & . Folsom, T. D. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s4-001 · Cited by 25
Trends in Use of Medications for Smoking Cessation in Medicare, 2007–2012
Jarlenski, M., Baik, S. H., & Zhang, Y. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.02.018 · Cited by 27
When is a point of view a conflict of interest?
Lenzer, J. (2016) · BMJ · doi:10.1136/bmj.i6194 · Cited by 25
Human pharmacology for addiction medicine
Quednow, B. B., & Herdener, M. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.017 · Cited by 28
“Nevertheless, bupropion and varenicline should be used with caution specifically in patients suffering from depression or having suicidal tendencies as both compounds likely increase the risk for depressive symptoms and suicide (Moore et al., 2011).”
BackgroundSmoking and suicide: biological and social evidence and causal mechanisms
Green, M., Turner, S. E., & Sareen, J. (2017) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2016-207731 · Cited by 27
Peng, C., Stokes, C. A., Mineur, Y. S., Picciotto, M. R., Tian, C., Eibl, C., Tomassoli, I., Guendisch, D., & Papke, R. L. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206904 · Cited by 26
“Such agents may have better compliance, fewer side effects, and may be particularly effective for treating the mood symptoms that occur during smoking cessation (Moore et al., 2011).”
BackgroundBuggy, Y., Cornelius, V. R., Fogg, C., Kasliwal, R., Layton, D., & Shakir, S. (2013) · Drug Safety · doi:10.1007/s40264-013-0046-6 · Cited by 21
“[19] using spontaneous reporting data, 13 % (1819/13.”
Cognition as a therapeutic target in late-life depression: Potential for nicotinic therapeutics
Zurkovsky, L., Taylor, W. D., & NEWHOUSE, P. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.032 · Cited by 20
Cunningham, F. E., Hur, K., Dong, D., Miller, D. R., Zhang, R., Wei, X., McCarren, M., Mosholder, A. D., Graham, D. J., Aspinall, S. L., et al. (2016) · Addiction · doi:10.1111/add.13329 · Cited by 22
An update on the pharmacotherapeutic interventions for smoking cessation
Barboza, J., Patel, R., Patel, P. P., & Hudmon, K. S. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197203 · Cited by 19
“Moore and colleagues evaluated the AERS data aforementioned and compared smoking cessation therapies to patients taking antibiotics, which were selected to capture suicidal behaviors in the general population [41].”
BackgroundKaduri, P., Voci, S. C., Zawertailo, L. A., Chaiton, M., McKenzie, K. J., & Selby, P. L. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000111 · Cited by 23
“…surveillance reports of serious neuropsychiatric symptoms, including aggression and hostility, exacerbation of preexisting psychiatric conditions, depressed mood, and suicidal thoughts and behavior, have limited its use in patients with psychiatric illness (Moore et al., 2011; Ahmed et al., 2013).”
BackgroundShah, D., Shah, A., Tan, X., & Sambamoorthi, U. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.03.021 · Cited by 20
“(Kuehn, 2009; Moore et al., 2009; Moore et al., 2011) Following these case reports, in February 2008, the FDA issued an alert to warn the prescribing physicians and consumers of the possible adverse events associated with these medications (US FDA, 2013).”
Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence
Houezec, J. L., & Aubin, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.818978 · Cited by 20
Varenicline as a Cause of Suicidal Outcomes
Hughes, J. R. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu275 · Cited by 19
Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands
Yenugonda, V. M., Xiao, Y., Levin, E. D., Rezvani, A. H., Tran, T. P., Al‐Muhtasib, N., Sahibzada, N., Xie, T., Wells, C., Slade, S. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008455 · Cited by 18
Chang, L., Mahmood, R., Qureshi, S., & Breder, C. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178104 · Cited by 16
Denton, T. T., Srivastava, P., Xia, Z., Chen, G., Watson, C. J. W., Wynd, A., & Lazarus, P. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00084 · Cited by 16
Chhabra, P. T., Chen, X., & Weiss, S. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0115-x · Cited by 16
“Studies have been published that compare AE reporting rates between drug classes and interpret these differences without fully considering the implications of reporting patterns on absolute and relative reporting rates [8, 15].”
BackgroundCurrent and Emerging Pharmacotherapeutic Options for Smoking Cessation
Carson‐Chahhoud, K., Brinn, M. P., Robertson, T. A., To-A-Nan, R., Esterman, A., Peters, M. J., & Smith, B. J. (2013) · Substance Abuse Research and Treatment · doi:10.4137/sart.s8108 · Cited by 20
Carney, G., Bassett, K. L., Maclure, M., Taylor, S., & Dormuth, C. R. (2020) · Addiction · doi:10.1111/add.14951 · Cited by 17
Liu, Y., Richardson, J. R., Tran, T. P., Al‐Muhtasib, N., Xie, T., Yenugonda, V. M., Sexton, H. G., Rezvani, A. H., Levin, E. D., Sahibzada, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000374 · Cited by 17
Fletcher, P. J., Li, Z., Silenieks, L. B., MacMillan, C., DeLannoy, I., & Higgins, G. A. (2018) · Addiction Biology · doi:10.1111/adb.12602 · Cited by 13
“In terms of side effects varenicline is associated with gastrointestinal disturbances and neuropsychiatric problems including suicidal and self-injurious behaviour, and aggression (Moore et al. 2011; Kuehn 2012; Cahill et al. 2016).”
BackgroundArancini, L., Bortolasci, C. C., Dodd, S., Dean, O. M., & Berk, M. (2019) · Trials · doi:10.1186/s13063-019-3628-5 · Cited by 13
Wu, J., Cippitelli, A., Zhang, Y., Debevec, G., Schoch, J., Ozawa, A., Yu, Y., Liu, H., Chen, W., Houghten, R. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01250 · Cited by 13
Thomas, K. H., Davies, N. M., Taylor, A. E., Taylor, G. M. J., Gunnell, D., Martin, R. M., & Douglas, I. (2020) · Addiction · doi:10.1111/add.15338 · Cited by 11
“Whereas studies using data from spontaneous reporting systems have reported an increase in psychiatric adverse effects such as suicide with varenicline use [14], large observational studies, randomized controlled trials (RCTs), meta-analyses and network meta-analyses of RCTs have not supported these findings [4,15–24].”
BackgroundEffects of smoking on health outcomes in bipolar disorder with a special focus on suicidal behavior
Dome, P., Gonda, X., & Rihmer, Z. (2012) · Neuropsychiatry · doi:10.2217/npy.12.51 · Cited by 12
Demesmaeker, A., Chazard, E., Vaïva, G., & Amad, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.04.006 · Cited by 12
Smoking Cessation Interventions for Lung Cancer Patients
Carson‐Chahhoud, K., Usmani, Z. A., Robertson, T. A., Mysore, S., & Brinn, M. P. (2013) · Lung Cancer Management · doi:10.2217/lmt.12.55 · Cited by 13
Shin, D. W., Suh, B., Chun, S., Cho, J., Yoo, S.-H., Kim, S. J., Oh, B., & Cho, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074904 · Cited by 10
“However, as shown in our study and others, more dependent smokers gravitate towards treatment [2,15,25,26], and such self-select would lead to a bias toward null [30].”
BackgroundResultHoffman, K. B., Overstreet, B. M., & Doraiswamy, P. M. (2013) · Drugs and Therapy Studies · doi:10.4081/dts.2013.e4 · Cited by 10
Varenicline and Suicide: Reconsidered and Reconciled
Niaura, R. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv247 · Cited by 10
Grebenstein, P. E., Harp, J. L., & Rowland, N. E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.012 · Cited by 9
“Cytisine use is associated with some of the same side effects as varenicline, but with notably decreased incidence of psychiatric symptoms (Moore et al. 2011; Tonstad et al. 2012; Tutka and Zatonski 2005), possibly due to differential activation of the α3β4 nAChR receptor subunit (Stokes and Papke…”
BackgroundHoffman, K. B., Dimbil, M., Kyle, R. F., Tatonetti, N. P., Erdman, C. B., Demakas, A., Chen, D., & Overstreet, B. M. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.12.1134 · Cited by 8
Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review
Chehab, O., & Dakik, H. A. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135040 · Cited by 8
Transient ischemic attack: Part II. Risk factor modification and treatment.
Simmons, B. B., Gadegbeku, A. B., & Cirignano, B. (2012) · PubMed · Cited by 13
Ansiedad, depresión y deshabituación tabáquica.
Pacheco, V. A., Gómez-Bastero, A., Morales, A. S. V., Crespo, E. L., Monserrat, S., & Rubio, T. M. (2016) · Adicciones · doi:10.20882/adicciones.761 · Cited by 13
Use of Pharmacotherapies for Smoking Cessation
Jarlenski, M., Chisolm, M. S., Kachur, S., Neale, D. M., & Bennett, W. L. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.10.019 · Cited by 7
“The finding that varenicline was almost never prescribed and filled might reflect current debate about its safety, particularly in patients with psychiatric disorders or other substance use.(24,25) The present results are also consistent with our and others’ previous work showing state Medicaid policies with more gene…”
ResultAdverse Neuropsychiatric Events Associated with Varenicline Use in Veterans: A Case Series
Cantrell, M. A., Argo, T. R., Haak, L., & Janney, L. (2012) · Issues in Mental Health Nursing · doi:10.3109/01612840.2012.692463 · Cited by 7
Are smoking cessation treatments associated with suicidality risk? An overview
Penberthy, J. K., Penberthy, J. M., Harris, M. R., Nanda, S., Ahn, J., Martinez, C. P., Osika, A. O., Slepian, Z. A., Forsyth, J. C., Starr, J. A., et al. (2016) · Substance Abuse: Research and Treatment · doi:10.4137/sart.s33389 · Cited by 6
Smoking and asthma: never the twain should meet
Sands, M. F. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.08.011 · Cited by 6
Arancini, L., Mohebbi, M., Berk, M., Dean, O. M., Bortolasci, C. C., Spolding, B., Zazula, R., & Dodd, S. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.002 · Cited by 6
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski, E., Jane, J. S., O’Brien, E. M., Edens, E. L., Arnaout, B., Kerfoot, K. E., Keegan, K. A., Weiner, J., Russo, M., & Petrakis, I. L. (2013) · Journal of Dual Diagnosis · doi:10.1080/15504263.2013.835163 · Cited by 6
Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy
Liakoni, E., & Benowitz, N. L. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002420 · Cited by 6
Signal detection for adverse event of varenicline in Korea Adverse Event Reporting System
Jang, M.-G., Gu, H.-J., Kim, J., & Shin, K. (2022) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2022.32.1.1 · Cited by 5
Tranel, D., McNutt, A., & Bechara, A. (2012) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e3182492a9c · Cited by 5
Chapman, S. F., & MacKenzie, R. (2012) · Public Health Ethics · doi:10.1093/phe/phr035 · Cited by 5
Wang, Y., Bos, J., Schuiling‐Veninga, C. C. M., Boezen, H. M., van Boven, J. F. M., Wilffert, B., & Hak, E. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042417 · Cited by 5
Liu, Y., Paige, M. A., Olson, T. T., Al‐Muhtasib, N., Xie, T., Hou, S., White, M. P., Cordova, A., Guo, J. L., Kellar, K. J., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.036 · Cited by 5
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?
Davies, N. M., Taylor, G. M. J., Taylor, A. E., Martin, R. M., Munafo, M. R., & Thomas, K. H. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00468-3 · Cited by 5
Le sevrage tabagique en oncologie thoracique
Ruppert, A.-M., Amrioui, F., Gounant, V., Wislez, M., Bouvier, F., & Cadranel, J. L. (2013) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2013.02.017 · Cited by 4
Metadata
- Authors
- Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S.
- Affiliations
- Institute for Safe Medication Practices (US)
- Wake Forest University Health Sciences (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Corresponding author
- Moore, Thomas J.
- ORCID
- Singh, Sonal
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-02
- Volume
- 6
- Issue
- 11
- Pages
- e27016
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3206890
- OpenAlex
- W2081459939
- Cited by
- 150
- References
- 29
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 11 · 2017: 10 · 2016: 17 · 2015: 11 · 2014: 9 · 2013: 30 · 2012: 27
- FWCI
- 15.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- smoking cessation, varenicline, bupropion, nicotine replacement therapy, suicidal behavior, self-harm, depression, adverse drug reactions, drug safety, FDA boxed warning, disproportionality analysis, serious adverse events
- MeSH terms
- Varenicline, Adult, Benzazepines, Depression, Female, Humans, Male, Middle Aged, Nicotine, Quinoxalines, Suicide, Smoking Cessation, Bupropion, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

